BSVN

Bank7 is a small, unusually well-run commercial bank whose stock is priced for mediocrity it isn't delivering. The core operating engine is elite for a $1.96B-asset lender: FY2025 tax-adjusted return on average equity of 18.51% (17.2% on period-end equity), pre-tax ROA of 3.12%, and an efficiency ratio of 40.24% — meaning it spends roughly 40 cents to earn a dollar of revenue, a level most banks envy. The balance sheet is fortress-like: $251M of equity (+17.7%), $245M of cash, $150M retained earnings (+28.7%), and effectively no long-term debt. At $49.59, or 11.0x $4.50 diluted EPS and ~1.9x book against a high-teens ROE, you are paying a below-market multiple for above-market profitability.

The headline blemish is that net income fell 5.8% and EPS 7.0% in FY2025, and the MD&A is explicit about why: the Fed's easing cycle (funds rate down to 3.50–3.75% from a 5.25–5.50% peak) compressed the net interest margin, with total-loan yields falling from 8.56% to 7.92% while the deposit-funded model repriced more slowly. This is a rate-cycle headwind, not a deterioration in the franchise. Underneath it, the bank grew total loans 15.0% ($209M) to $1.61B and deposits 12.2% to $1.70B — genuine organic share gains in Oklahoma, Dallas/Fort Worth and Kansas. Credit stayed clean: the provision was just $700K (up from $0, and management ties it directly to loan growth, not losses), and the allowance is $19.4M, or ~1.2% of loans, up modestly from $17.9M.